01 1Hetero Drugs
01 1RIZATRIPTAN BENZOATE USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-05
Pay. Date : 2023-05-04
DMF Number : 26017
Submission : 2012-05-02
Status : Active
Type : II
20
Hetero Drugs Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIZATRIPTAN BENZOATE USP, with a corresponding US DMF Number 26017.
Remarkably, this DMF maintains an Active status since its submission on May 02, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 05, 2023, and payment made on May 04, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II
